Inventor · disambiguated record
Elizabeth Shpall
Also filed as: SHPALL ELIZABETH · SHPALL ELIZABETH J
10 granted patents·30 pending applications·15 citations·filing 2009–2024
83Inventor score
Top patents by PatentIndex Score
40 records- 0184US11344578B2Immune cells expressing engineered antigen receptorsUNIV TEXAS·Filed 2018·Granted May 31, 2022·2 cites·25 claims
- 0283US8728806B2Methods and compositions related to Th-1 dendritic cellsDECKER WILLIAM K·Filed 2009·Granted May 20, 2014·10 cites·30 claims
- 0375US12403093B2Methods for production of MSC-derived exosomesUNIV TEXAS·Filed 2023·Granted Sep 2, 2025·0 cites·22 claims
- 0475US11766402B2Methods for production of MSC-derived exosomesUNIV TEXAS·Filed 2018·Granted Sep 26, 2023·1 cites·37 claims
- 0574US9333248B2Methods and composition related to Th-1 dendritic cellsUNIV TEXAS·Filed 2014·Granted May 10, 2016·1 cites·29 claims
- 0668US11154572B2Methods of treatment with natural killer cells matched for killer immunoglobulin receptor typeUNIV TEXAS·Filed 2016·Granted Oct 26, 2021·1 cites·18 claims
- 0765US2022265718A1Immune cells expressing engineered antigen receptorsUNIV TEXAS·Filed 2022·Application pending·0 cites
- 0865US2019262442A1METHODS AND COMPOSITIONS RELATED TO Th-1 DENDRITIC CELLSUNIV TEXAS·Filed 2019·Application pending·0 cites
- 0962US12473336B2Methods for activation and expansion of natural killer cells and uses thereofUNIV TEXAS·Filed 2019·Granted Nov 18, 2025·0 cites·16 claims
- 1062US12466867B2Methods for activation and expansion of natural killer cells and uses thereofUNIV TEXAS·Filed 2021·Granted Nov 11, 2025·0 cites·10 claims
- 1161US2025228942A1Methods for activation and expansion of engineered natural killer cells and combinations with antibodiesUNIV TEXAS·Filed 2023·Application pending·0 cites
- 1260US9993537B2Methods and compositions related to Th-1 dendritic cellsUNIV TEXAS·Filed 2016·Granted Jun 12, 2018·0 cites·27 claims
- 1360US2024125765A1A method for selection of cryopreserved cord blood units for the manufacture of engineered natural killer cells with enhanced potency against cancerUNIV TEXAS·Filed 2022·Application pending·0 cites
- 1460US2024336699A1Enhanced chimeric antigen receptors and use thereofUNIV TEXAS·Filed 2024·Application pending·0 cites
- 1558US2024331837A1Selection of viral-specific cytotoxic t-cell lines for the management of viral infectionsUNIV TEXAS·Filed 2022·Application pending·0 cites
- 1655US2024382593A1Antibody loaded immune cells and methods for use in cancer treatmentUNIV TEXAS·Filed 2022·Application pending·0 cites
- 1755US2021253729A1Enhanced chimeric antigen receptors and use thereofUNIV TEXAS·Filed 2021·Application pending·0 cites
- 1854US2024252539A1Chimeric antigen receptor to target hla-g-positive cancersUNIV TEXAS·Filed 2022·Application pending·0 cites
- 1953US2024189357A1Chimeric antigen receptors to target cd5-positive cancersUNIV TEXAS·Filed 2022·Application pending·0 cites
- 2053US2023220351A1Large-scale production of exosomes from primed mesenchymal stromal cells for clinical useUNIV TEXAS·Filed 2021·Application pending·0 cites
- 2152US2024165162A1Methods for activation and expansion of natural killer cells and combinations with bispecific antibodiesUNIV TEXAS·Filed 2022·Application pending·0 cites
- 2252US2023074303A1Cell immunotherapy for the treatment of cancerUNIV TEXAS·Filed 2021·Application pending·0 cites
- 2352US2023159618A1Enhanced chimeric antigen receptors and use thereofUNIV TEXAS·Filed 2018·Application pending·0 cites
- 2452US2024245614A1Production of therapeutic mesenchymal stem cell-derived exosomesUNIV TEXAS·Filed 2022·Application pending·0 cites
- 2552US2025281612A1Cd27-extracellular domain car to target cd70-positive tumorsUNIV TEXAS·Filed 2022·Application pending·0 cites
- 2651US2022033778A1Methods for ex vivo expansion of natural killer cells and use thereofUNIV TEXAS·Filed 2019·Application pending·0 cites
- 2751US2022033848A1A modular, polycistronic vector for car and tcr transductionUNIV TEXAS·Filed 2019·Application pending·0 cites
- 2851US2022023343A1Suicide geneUNIV TEXAS·Filed 2019·Application pending·0 cites
- 2949US2022378739A1Natural killer cell immunotherapy for the treatment of glioblastoma and other cancersUNIV TEXAS·Filed 2020·Application pending·0 cites
- 3048US2023210902A1Sars-cov-2-specific t cellsUNIV TEXAS·Filed 2021·Application pending·0 cites
- 3148US2023383257A1Production of megakaryocytes and platelets in a co-culture systemUNIV TEXAS·Filed 2021·Application pending·0 cites
- 3247US2022325245A1Methods for production of car-nk cells and use thereofUNIV TEXAS·Filed 2020·Application pending·0 cites
- 3345US2022288121A1Cell cryopreservation mediumUNIV TEXAS·Filed 2020·Application pending·0 cites
- 3444US2021393698A1Methods for the expansion of mesenchymal stromal cellsUNIV TEXAS·Filed 2019·Application pending·0 cites
- 3544US2021230548A1Natural killer cells engineered to express chimeric antigen receptors with immune checkpoint blockadeUNIV TEXAS·Filed 2019·Application pending·0 cites
- 3644US2023045174A1Large-scale combined car transduction and crispr gene editing of msc cellsUNIV TEXAS·Filed 2020·Application pending·0 cites
- 3743US10821134B2BK virus specific T cellsUNIV TEXAS·Filed 2018·Granted Nov 3, 2020·0 cites·21 claims
- 3843US2020390815A1Universal antigen presenting cells and uses thereofUNIV TEXAS·Filed 2019·Application pending·0 cites
- 3942US2020113939A1Regulatory b cells and uses thereofUNIV TEXAS·Filed 2017·Application pending·0 cites
- 4040US2021147800A1Methods for producing regulatory immune cells and uses thereofUNIV TEXAS·Filed 2018·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Elizabeth Shpall files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →